Scientific Publications
The following publications provide additional information on ReoPro and do not represent an exhaustive list of articles. For hard copies, please see your local ReoPro Representative. If you do not know who she/he is, please call 1-800-LILLY-RX for their contact information. Please reference the item code associated with each publication when talking to your ReoPro Representative.
|
Additional References |
Item Code |
|---|---|
|
The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled
trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa
blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa
Inhibitor for Stenting. Lancet. 1998;352(9122):87-92. |
AB13424 |
|
Klootwijk P, et al. Reduction of recurrent ischemia with abciximab
during continuous ECG-ischemia monitoring in patients with unstable
angina refractory to standard treatment (CAPTURE). Circulation. 1998;98(14):1358-1364. |
AB14969 |
|
Antoniucci D, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42(11):1879-1885. |
AB30064 |
|
Neumann FJ, et al. Effect of glycoprotein IIb/IIIa receptor blockade
with abciximab on clinical and angiographic restenosis rate after the
placement of coronary stents following acute myocardial infarction. J
Am Coll Cardiol . 2000;35(4):915-921. |
AB30336 |
|
Lincoff AM, Abciximab and bleeding during coronary surgery: results
from the EPILOG and EPISTENT trials. Improve Long-term Outcome with
abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition
in STENTing. Ann Thorac Surg. 2000;70(2):516-526. |
AB30338 |
|
Lincoff AM, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999;341(5):319-327. |
AB30340 |
|
Islam MA, et al. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol. 2002;90(9):916-921. |
AB30342 |
|
Hamm CW, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340(21):1623-1629. |
AB30343 |
|
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336(24):1689-1696. |
AB30344 |
|
Cura FA, et al. Pronounced benefit of coronary stenting and adjunctive
platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic
lesions. Circulation. 2000;102(1):28-34. |
AB30345 |
|
The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349(9063):1429-1435. |
AB30346 |
|
Tcheng JE, et al. Benefits and risks of abciximab use in primary angioplasty
for acute myocardial infarction: the Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003;108(11):1316-1323. |
AB30347 |
|
Montalescot G, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895-1903. |
AB30348 |
|
Kandzari DE, et al. Improved clinical outcomes with abciximab therapy
in acute myocardial infarction: a systematic overview of randomized
clinical trials. Am Heart J. 2004;147(3):457-462. |
AB31495 |
|
Lage MJ, Impact of abciximab versus eptifibatide on length of hospital
stay for PCI patients. Catheter Cardiovasc Interv. 2001;53(3):296-303. |
AB31508 |
|
Topol EJ, et al. Outcomes at 1 year and economic implications of platelet
glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting:
results from a multicentre randomised trial. EPISTENT Investigators.
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999;354(9195):2019-2024. |
AB31509 |
|
Topol EJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888-1894. |
AB31510 |
|
Antoniucci D, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109(14):1704-1706. |
AB32365 |
|
Mehran R, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol. 2004;43(8):1348-1354. |
AB32498 |
|
Brener SJ, et al. Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry. Eur Heart J. 2003;24(7):630-638. |
AB34817 |
